A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
about
Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature.The use of molecular analyses in voided urine for the assessment of patients with hematuria.Size-based enrichment of exfoliated tumor cells in urine increases the sensitivity for DNA-based detection of bladder cancer.Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM.Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer.Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder CancerPromoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.UroMark-a urinary biomarker assay for the detection of bladder cancer.Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids.Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies.Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder CancerUrothelial Bladder Cancer Urinary Biomarkers.Non-blood circulating tumor DNA detection in cancer.DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.Validation of a protein panel for the noninvasive detection of recurrent non-muscle invasive bladder cancer.DNA methylation in urothelial carcinoma.Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer
P2860
Q34579038-C4874AAE-F01B-4D90-AB5C-59523D76AC4AQ35021819-66EB2119-879A-469A-8418-5EA6C94B3BCCQ35147519-9B73D257-6992-472D-A949-D61A22E1D650Q35198309-73C34932-DB05-44E2-A2E9-7203A4DDDF83Q35685060-FD0364C3-FA9C-4B5E-A3FF-8A2118A9F5EAQ35930911-4A864377-9127-4F9B-9AAE-DE37C87DF324Q36120837-DCEB7852-6B74-40DA-922C-B36FDE1B181EQ37615895-92B6823E-705D-4A5D-82BB-649652FD20CAQ37653469-05A59839-2332-4675-B31E-3700A0491968Q38216129-3002F29C-FC6D-4640-B228-4E254B90F55AQ38297729-D3FFB3D6-B42C-4A1B-B925-8F8F641F267AQ38921522-5F3FE801-7B2B-4654-B0A8-D3D4D04BDFDFQ38967481-ACB80572-DAB1-490A-86A4-9386BA923387Q42253044-2AB377D5-ABCC-4A16-AE03-8A1F2A4BF431Q43809210-6EE9C774-9B27-440A-AAEA-7965DE261194Q51240116-4BC8FB43-EBEE-4B73-81B3-C8A9576DB93BQ53691833-6DD3841E-BFD5-4D8F-8D86-15AD706DD494Q58862326-CC55447F-EFBE-4FF5-ABBE-FD059B128521
P2860
A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A 3-plex methylation assay com ...... ladder cancer in voided urine.
@en
A 3-plex methylation assay com ...... ladder cancer in voided urine.
@nl
type
label
A 3-plex methylation assay com ...... ladder cancer in voided urine.
@en
A 3-plex methylation assay com ...... ladder cancer in voided urine.
@nl
prefLabel
A 3-plex methylation assay com ...... ladder cancer in voided urine.
@en
A 3-plex methylation assay com ...... ladder cancer in voided urine.
@nl
P2093
P1476
A 3-plex methylation assay com ...... ladder cancer in voided urine.
@en
P2093
Angela A G van Tilborg
Chris H Bangma
Ellen C Zwarthoff
Hester Lingsma
Nikki van Leeuwen
Roy Masius
Torben F Orntoft
Willemien Beukers
P304
P356
10.1158/1078-0432.CCR-12-3276
P407
P577
2013-07-10T00:00:00Z